Drug Approval | January 28, 2023
USFDA provides exception to Glenmark's Baddi facility
The company will engage with the agency to resolve the import alert at the earliest.
The company will engage with the agency to resolve the import alert at the earliest.
Cell sorting technology supports researchers advancing new therapies
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Granules now have a total of 53 ANDA approvals from USFDA
USFDA issued issued Form 483 with nine observations, which will be addressed within stipulated time.
The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
He was previously associated with renowned companies such as Granules India Ltd, Dr. Reddy’s Laboratories ltd & Aptar Group
Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
Subscribe To Our Newsletter & Stay Updated
